Drugs / HepB mAb19
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07610772 | Apr 2026 → Apr 2028 expected | chronic hepatitis B virus infection, hepatitis D virus infection | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06668727 | Aug 2024 → Aug 2027 expected | chronic hepatitis B virus infection | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05856890 | Aug 2023 → Dec 2027 expected | hepatitis B virus infection | Rockefeller University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepB mAB19 | “All study participants will receive two or three dosis of the antibody, HepB mAB19, and will be followed for 60 weeks after the first HepB mAb19 infusion.” NCT07610772 ↗4“HepB mAb-19 was isolated and cloned from an HBsAg vaccinated individual at the Rockefeller University.” NCT06668727 ↗ |
| Action | Inhibit | “HepB mAb19, which effectively reduces the amount of circulating HBV antigens.” NCT07610772 ↗ |
| Modality | Monoclonal antibody | “HepB mAb19 is a human mAb of IgG1kappa isotype” NCT05856890 ↗ |
| Route | Intravenous | “Single intravenous infusion of HepB mAb19” NCT05856890 ↗ |